Barry Quart

1.6k total citations
28 papers, 1.2k citations indexed

About

Barry Quart is a scholar working on Surgery, Nephrology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Barry Quart has authored 28 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Surgery, 6 papers in Nephrology and 6 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Barry Quart's work include Gout, Hyperuricemia, Uric Acid (6 papers), HIV Research and Treatment (5 papers) and Anesthesia and Pain Management (4 papers). Barry Quart is often cited by papers focused on Gout, Hyperuricemia, Uric Acid (6 papers), HIV Research and Treatment (5 papers) and Anesthesia and Pain Management (4 papers). Barry Quart collaborates with scholars based in United States, Australia and Austria. Barry Quart's co-authors include S. Hardy, Donald Archibald, Michael H. Lehmann, Daniel J. MacNeil, Li‐Tain Yeh, Neil J. Clendeninn, Kimberly J. Manhard, Jeffrey N. Miner, Zancong Shen and Michael S. Saag and has published in prestigious journals such as Circulation, Cancer Research and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Barry Quart

28 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Barry Quart United States 15 376 331 244 235 232 28 1.2k
Robert Cramb United Kingdom 22 327 0.9× 159 0.5× 718 2.9× 96 0.4× 52 0.2× 50 1.7k
Thomas Demant Germany 21 370 1.0× 241 0.7× 773 3.2× 80 0.3× 390 1.7× 41 1.9k
Julie Borland United States 26 227 0.6× 309 0.9× 249 1.0× 21 0.1× 1.3k 5.4× 52 2.0k
Isabelle Antony France 18 953 2.5× 118 0.4× 223 0.9× 18 0.1× 198 0.9× 39 1.5k
Rick Greupink Netherlands 24 46 0.1× 302 0.9× 134 0.5× 36 0.2× 178 0.8× 70 1.4k
Donald L. Kaminski United States 25 83 0.2× 183 0.6× 1.2k 4.8× 63 0.3× 119 0.5× 87 2.1k
Karl Brendel France 11 51 0.1× 94 0.3× 90 0.4× 33 0.1× 168 0.7× 19 1.1k
Gail Mayo United States 14 274 0.7× 135 0.4× 152 0.6× 8 0.0× 183 0.8× 17 1.4k
D B Jones Australia 21 39 0.1× 161 0.5× 561 2.3× 55 0.2× 91 0.4× 39 2.2k
Stéphane Bouchet France 22 66 0.2× 356 1.1× 73 0.3× 86 0.4× 111 0.5× 56 1.6k

Countries citing papers authored by Barry Quart

Since Specialization
Citations

This map shows the geographic impact of Barry Quart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barry Quart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barry Quart more than expected).

Fields of papers citing papers by Barry Quart

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barry Quart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barry Quart. The network helps show where Barry Quart may publish in the future.

Co-authorship network of co-authors of Barry Quart

This figure shows the co-authorship network connecting the top 25 collaborators of Barry Quart. A scholar is included among the top collaborators of Barry Quart based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barry Quart. Barry Quart is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Quart, Barry, et al.. (2019). Mechanism of action of HTX-011: a novel, extended-release, dual-acting local anesthetic formulation for postoperative pain. Regional Anesthesia & Pain Medicine. 45(2). 117–123. 40 indexed citations
2.
Cravets, Matt, et al.. (2018). Bioequivalence of HTX-019 (aprepitant IV) and fosaprepitant in healthy subjects: a Phase I, open-label, randomized, two-way crossover evaluation. Drug Design Development and Therapy. Volume 12. 429–435. 22 indexed citations
3.
Cravets, Matt, et al.. (2018). Safety of HTX-019 (intravenous aprepitant) and fosaprepitant in healthy subjects. Future Oncology. 14(27). 2849–2859. 19 indexed citations
4.
5.
Miner, Jeffrey N., Philip K. Tan, David Hyndman, et al.. (2016). Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. Arthritis Research & Therapy. 18(1). 214–214. 107 indexed citations
6.
Shen, Zancong, V. Hingorani, Kimberly J. Manhard, et al.. (2015). Pharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult males. Drug Design Development and Therapy. 9. 3423–3423. 43 indexed citations
7.
Fleischmann, R., Bradley M. Kerr, Li‐Tain Yeh, et al.. (2014). Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia. Lara D. Veeken. 53(12). 2167–2174. 81 indexed citations
8.
9.
Yeh, Li‐Tain, Zancong Shen, B M Kerr, et al.. (2012). AB1064 No clinically meaningful drug interactions expected between lesinurad, a novel oral uricosuric agent, and drugs most commonly used by gout patients. Annals of the Rheumatic Diseases. 71. 699–699. 1 indexed citations
10.
Moyle, Graeme, Marta Boffito, Albrecht Stoehr, et al.. (2010). Phase 2a Randomized Controlled Trial of Short-Term Activity, Safety, and Pharmacokinetics of a Novel Nonnucleoside Reverse Transcriptase Inhibitor, RDEA806, in HIV-1-Positive, Antiretroviral-Naive Subjects. Antimicrobial Agents and Chemotherapy. 54(8). 3170–3178. 35 indexed citations
11.
Iverson, Cory, Gary Larson, Chon Lai, et al.. (2009). RDEA119/BAY 869766: A Potent, Selective, Allosteric Inhibitor of MEK1/2 for the Treatment of Cancer. Cancer Research. 69(17). 6839–6847. 153 indexed citations
12.
Miampamba, Marcel, et al.. (2008). RDEA119, a Potent and Highly Selective MEK1/2 Inhibitor Is Beneficial in Dextran Sulfate Sodium (DSS)-Induced Chronic Colitis in Mice. The American Journal of Gastroenterology. 103. S453–S453. 2 indexed citations
13.
Yü, George, et al.. (2000). Statistical Methodology for Maximally HIV-RNA Suppressive Treatments in HIV-Infected Subjects. Drug Information Journal. 34(2). 617–629. 1 indexed citations
14.
Powderly, William G., Michael S. Saag, Sharon Chapman, et al.. (1999). Predictors of optimal virological response to potent antiretroviral therapy. AIDS. 13(14). 1873–1880. 150 indexed citations
15.
Kerr, Bradley M., et al.. (1998). Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate.. PubMed. 26(7). 609–16. 91 indexed citations
16.
Lehmann, Michael H., S. Hardy, Donald Archibald, Barry Quart, & Daniel J. MacNeil. (1996). Sex Difference in Risk of Torsade de Pointes With d,l- Sotalol. Circulation. 94(10). 2535–2541. 346 indexed citations
17.
Singh, Bramah N., Richard Kehoe, Raymond L. Woosley, Melvin M. Scheinman, & Barry Quart. (1995). Multicenter trial of sotalol compared with procainamide in the suppression of inducible ventricular tachycardia: A double-blind, randomized parallel evaluation. American Heart Journal. 129(1). 87–97. 33 indexed citations
18.
Pool, Peter E. & Barry Quart. (1988). Treatment of ectopic atrial arrhythmias and premature atrial complexes in adults with encainide. The American Journal of Cardiology. 62(19). L60–L62. 9 indexed citations
19.
Quart, Barry, et al.. (1986). Drug interaction studies and encainide use in renal and hepatic impairment. The American Journal of Cardiology. 58(5). C104–C113. 18 indexed citations
20.
Quart, Barry, et al.. (1982). The effect of mild alcohol consumption on the metabolism of acetaminophen in man.. PubMed. 38(1). 57–70. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Robert Cramb Breakdown of academic impact, for papers by Thomas Demant Breakdown of academic impact, for papers by Julie Borland Breakdown of academic impact, for papers by Isabelle Antony Breakdown of academic impact, for papers by Rick Greupink Breakdown of academic impact, for papers by Donald L. Kaminski Breakdown of academic impact, for papers by Karl Brendel Breakdown of academic impact, for papers by Gail Mayo Breakdown of academic impact, for papers by D B Jones Breakdown of academic impact, for papers by Stéphane Bouchet
Rankless by CCL
2026